Rx-360 summary of FDA Final Guidance Refuse to Accept Policy for 510(k)s
Rx-360 has releases a summary of FDA Final Guidance Refuse to Accept Policy for 510(k)s.
FDA has published a revised final guidance document entitled "Refuse to Accept Policy for 510(k)s," which will go into effect on 1 October 2015. This guidance will replace the prior version of the guidance issued on 31 December 2012. The purpose of the guidance is to describe FDA's initial screening process for 510(k) submissions, which is used to determine if the submission is sufficiently complete to undergo substantive review. The guidance has been updated to incorporate internal FDA and stakeholder feedback on the implementation of the "Refuse to Accept" (RTA) process.
Key revisions include
(i) streamlining of checklists to reflect actual review practice, additional flexibility to permit reviewer discretion to accept files lacking certain non-critical information
(ii) incorporation of guidance issued since the release of the prior version (e.g., recently issued device reprocessing guidance)
(iii) addition of a page number column for industry to identify the location of required elements in the submission
(iv) revisions to checklist items that could lead to substantive review during the screening process (i.e., to ensure only administrative review occurs during the screening process).
In addition, this version makes clear that FDA encourages submitters to complete and submit the relevant acceptance checklist with their submission to identify the location of supporting information for each RTA element.
This guidance document supersedes three existing guidance documents titled "Refuse to Accept Policy for 510(k)s" issued on 31 December 2012; "Center for Devices and Radiological Health's Premarket Notification (510(k)) Refuse to Accept Policy" issued on 30 June 30 1993; and "510(k) Memorandum K94-1" issued on 20 May 1994.
To view or download the FDA Guidance, click here
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance